The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Editas Medicine's Revenue for the
three
months ended in Mar. 2026 was $2.83 Mil. Editas Medicine's average Accounts Receivable for the
three
months ended in Mar. 2026 was $8.88 Mil.
Hence, Editas Medicine's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.32.
Editas Medicine (NAS:EDIT) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Editas Medicine Receivables Turnover Related Terms
Editas Medicine Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDIT vs SGMT, AUTL, FBRX: Receivables Turnover Comparison
For the Biotechnology subindustry, Editas Medicine's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a Receivables Turnover of 0.32 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #286 out of 840 companies in the Biotechnology industry, placing it in the top 34%.
Is Editas Medicine's Receivables Turnover too high?
Editas Medicine's current Receivables Turnover is 0.32. The Biotechnology industry median Receivables Turnover is 5.30. Editas Medicine's value of 0.32 is 94% below this industry median. Based on the distribution chart, Editas Medicine ranks #286 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Receivables Turnover compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #286 out of 840 companies for Receivables Turnover. This puts Editas Medicine in the upper half of its industry. The industry median Receivables Turnover is 5.30. Editas Medicine's value of 0.32 is 94% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Receivables Turnover of 0.32 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Receivables Turnover is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.84, compared to a current price of $3.26 — trading 77.2% above its estimated fair value. The current Receivables Turnover is 0.32 and 94% below the Biotechnology industry median of 5.30. Editas Medicine's overall GF Score™ is 45/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Receivables Turnover is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.26 is trading 77.2% above its estimated GF Value™ of $1.84.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Receivables Turnover: 0.32
GF Value™: $1.84 vs. price of $3.26 (77.2% above fair value)
Industry Position: 94% below the Biotechnology median (#286 of 840)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score
Get the complete analysis for EDIT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
